

Review Article

The Newest Hypothesis about Vitiligo: Most of the Suggested Pathogeneses of Vitiligo Can Be Attributed to Lack of One Factor, Zinc- α 2-Glycoprotein

Nooshin Bagherani

Nooshin Bagherani's Office, 2nd Floor, Taha Physicians' Building, 40-Meter Street, Khoramshahr, Khuzestan Province, Iran

Correspondence should be addressed to Nooshin Bagherani, nooshinbagherani@yahoo.com

Received 15 March 2012; Accepted 18 April 2012

Academic Editors: E. Alpsy, H. Takahashi, and A. Zalewska

Copyright © 2012 Nooshin Bagherani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Zinc- α 2-glycoprotein (ZAG) is a recently identified adipokine, assigned to the chromosome 7q22.1. It is a multidisciplinary protein, which is secreted in various body fluids. The ZAG plays roles in lipolysis, regulation of metabolism, cell proliferation and differentiation, regulation of melanin synthesis, cell adhesion, immunoregulation, and so forth. Vitiligo is the most common depigmenting skin disorder, characterized by acquired, progressive, and circumscribed amelanosis of the skin and hair. It commonly begins in childhood or young adulthood. The pathogenesis of this disorder is uncertain, but it appears to be dependent on the interaction of genetic, immunological, and neurological factors. For the first time, we pointed the probable association between ZAG and vitiligo. Herein, I have described this association in different views. By confirming this association, a surprising progression will occur in the treatment of this prevalent debilitating disease.

1. Introduction of Zinc- α 2-Glycoprotein

Zinc- α 2-glycoprotein (ZAG), a recently identified adipokine [1–4], is a 41,000 Da glycoprotein, secreted by a variety of normal epithelia [5]. For the first time, this 41 kDa single-chain polypeptide [6] was reported in human serum and subsequently purified in 1961 [7]. It was named for its electrophoretic mobility and for its ability to be precipitated by zinc salts [8–10].

The gene of ZAG, assigned to the chromosome 7q22.1, comprises four exons and three introns [7]. Its first full polypeptide sequence was identified by Araki et al. [11]. The molecule of ZAG has three domains, named α 1, α 2, and α 3 [7]. The amino acids of α 1 and α 2 domains are highly conserved [12], indicative of the functional importance of the groove in the biological functions. On the other hand, the α 3 domain is less conserved, indicative of species specificity and evolutionary constrains [7]. The main function of ZAG gene is the decomposition of fat and reduced fat content [13]. The serum ZAG can easily be detected by tetramethylethylenediamine-enhanced photoluminescent imaging [14].

There is high degree of similarity between ZAG and antigen-presenting molecules such as class I MHC molecules both at sequence and structural levels. The ZAG is considered as a member of immunoglobulin gene superfamily [7] based on its structure so that its 2.8 angstrom crystal structure [15] has a large groove analogous to class I MHC peptide-binding grooves [7, 12, 15, 16]. Unlike other MHC molecules, ZAG is not membrane bound; so, it appears that its function is different from the peptide presentation and T-cell interaction functions of class I MHC [7, 17]. Moreover, instead of a peptide, the ZAG contains a nonpeptidic compound in the groove, which plays a role in lipid catabolism under normal and pathological conditions [15]. This structure of groove also reflects its role in immunoregulation [7]. Furthermore, it appears that ZAG is the sole soluble member of immunoglobulin gene superfamily that is implicated in cachexia [18].

The ZAG is a multidisciplinary protein, which is secreted in various body fluids [7] and is found to be ubiquitously and constitutively expressed [18]. Its presence and expression have normally been described in the following sites: normal human fluids such as serum, seminal fluid, saliva, sweat,

milk, cerebrospinal fluid, urine and amniotic fluid, kidney extract [7], liver, breast, lung, and prostate [17]. The ZAG is synthesized by adipocytes, liver, epithelial cells of prostate, normal epidermal and buccal epithelia [7]. ZAG secretion by differentiated human adipocytes is abundant [2], and it appears that ZAG has an autocrine/paracrine role in adipose tissue function [17]. In one study on mice, Tzanavari et al. detected ZAG mRNA from one day of birth in subcutaneous fat, which is the main site of ZAG synthesis postnatally. They showed that ZAG mRNA and protein levels fall significantly at weaning and thereafter. At the end, they concluded that the downregulated ZAG expression in white fat depots at weaning, when fat mass is expanded substantially, suggests that ZAG might be involved in the postnatal development of adipose tissue mass [3].

It appears that renal filtration is an important route for eliminating ZAG; hence, markers of renal function should be considered in studies on ZAG physiology [19].

2. Regulation of ZAG Expression

The gene expression of ZAG is predominately regulated by glucocorticoids [7, 20], androgens, and progestins [7]. The ZAG itself has been revealed to induce ZAG expression in adipocytes [20]. This ability of ZAG in inducing its own expression can explain the much greater effect of ZAG on lipolysis *in vivo* than its effect on lipolysis *in vitro* [20, 21].

Glucocorticoids are able to enhance ZAG expression [20, 22, 23]. The findings suggest that induction of ZAG expression may play role in the action of glucocorticoids. It appears that glucocorticoids induce β 3-adrenoreceptor in adipocytes by which it amplifies the induction of ZAG expression [20]. Furthermore, eicosapentaenoic acid can downregulate ZAG expression through interference with glucocorticoid signaling [23]. The mechanism by which induction of β 3-adrenoreceptor leads to an increase in ZAG expression is not known [20, 21].

It has been shown that the expression of ZAG is increased by the selective β 3-adrenoreceptor agonist BRL37344, suggesting that the sympathetic system can play a role in the regulation of ZAG expression [20] and that the induction of ZAG is mediated through β 3-adrenoreceptor [16, 20].

Interferon- γ (IFN- γ) is a potential mediator of the increased ZAG expression in cachexia. It has been shown that IFN- γ can strongly upregulate expression of ZAG in human epithelial cell lines [20, 24].

Studies showed that tumor necrosis factor- α (TNF- α), a major product of macrophages [25], can modulate ZAG expression and secretion by human adipocytes [17, 25]. In one study, Sanders and Tisdale have demonstrated that ZAG expression can be regulated particularly through TNF- α and the PPAR-gamma nuclear receptor [26]. TNF- α can decrease ZAG expression and secretion [4, 25], while the PPAR-gamma agonist rosiglitazone induces an increase in ZAG level [26]. It appears that the effect of TNF- α on ZAG is time-dependent; in other words, this effect appears chronic rather than acute [17]. Studies have shown that proinflammatory cytokines and chemokines such as interleukin-6 (IL-6),

leptin, IL-8, MCP-1, and RANTES can upregulate ZAG expression in adipocytes [25].

3. Biologic Roles of ZAG in Human

3.1. Lipolysis and Lipid Mobilization. The ZAG is a natural adipocyte factor found in both white and brown adipose tissue [20]. Although the exact role of ZAG in adipose tissue remains to be clarified, it appears that its expression is inversely related to adiposity [27]. In mice it has been revealed that the action of ZAG is associated with downregulated lipogenic enzymes and upregulated lipolytic enzyme expression in adipose tissue [28].

The ZAG is closely related to obesity [2, 27–29]. Serum ZAG level is inversely correlated with percentage of body fat, fat mass [2, 28, 29], body weight [28, 29], body mass index [2, 28], waist circumference [28, 30], and hip circumference [28]. The ZAG can cause highly significant, time-dependent decrease in body weight. This body weight loss can entirely be attributed to the loss of body fat [21]. Genetic studies have suggested that ZAG may be a candidate gene for body weight regulation [27]. On the other hand, the clearance of ZAG in the circulation may be altered in obesity [17].

The ZAG is known to promote lipolysis through stimulation of adenylate cyclase in a GTP-dependent process via binding through β 3-adrenoreceptor [7, 21]. Russell and Tisdale showed that ZAG not only induces direct lipolysis, but also sensitizes adipose tissue to other lipolytic stimuli [31]. Moreover, ZAG via increasing uncoupling protein-1 (UCP-1) expression in brown adipose tissue can lead to lipolysis [21, 26].

Glucocorticoid-mediated upregulation of ZAG expression in white and brown adipose tissues results in lipolysis [7, 23]; hence, induction of lipolysis by corticosteroids can be attenuated by anti-ZAG antisera [7].

The ZAG is responsible for cachexia or lipid catabolism seen in cancer patients [7, 32]. It appears that this process is due to the upregulation of ZAG secondary to increased level of circulatory glucocorticoids [7, 33].

3.2. Regulation of Metabolism. The ZAG can stimulate energy utilization in adipose tissue and skeletal muscle by upregulation of UCP isoforms and GLUT4. Findings have shown that ZAG can lead to phosphorylation of AMP kinase- α and ACC, thereby activating a pathway central to the regulation of energy metabolism [34]. Russell and Tisdale have shown that rats treated with ZAG show a progressive decrease in body weight, without any decrease in food intake, but with a rise in body temperature [31, 35]. They showed that loss of adipose tissue accompany an increase in lean body mass [35]. In another study, they showed that ZAG can decrease phosphorylation of both double-stranded RNA-dependent protein kinase in muscles of diabetic mice; thereby it can attenuate the process of skeletal muscle atrophy. This effect is interestingly shown in gastrocnemius but not soleus muscle [36].

The circulating ZAG is negatively correlated with fasting insulin, homeostasis model assessment of insulin resistance [2, 19], C reactive protein [2], and leptin [2, 19, 30]. On the

other hand, ZAG is positively correlated with adiponectin [2, 30].

The ZAG plays a role in lipid metabolism [37]. It also can influence adipocyte metabolism locally [2]. Serum level of ZAG is associated with the serum levels of cholesterol [37]. The ZAG genotype appears to be associated with total cholesterol and low-density-lipoprotein cholesterol. ZAG also correlates with glucose, creatinine, and uric acid. Stejskal et al. introduced ZAG as a marker for glucose metabolism [38].

In detecting of doping with recombinant erythropoietins by isoelectric focusing and western double blotting, ZAG interacts nonspecifically [39].

3.3. Fertilization. The presence of ZAG in human seminal fluid is 6 times more than that in the human serum, which suggests its role in fertilization [7]. The lipid metabolism pathway is a significant mechanism for modulating sperm motility; so, it is predicted that ZAG can play a vital role in sperm motility via such process [7, 40]. On the other hand, ZAG can bind to the sperm membrane and initiate motility which is directly associated to cAMP levels in semen [7]. Ding et al. have demonstrated that ZAG and $\alpha 1$ -antitrypsin, related to the forward motility of spermatozoa in human seminal plasma, played important roles during maturation of spermatozoa, from the epididymis through fertilization in the female reproductive tract [41].

3.4. Regulation of Melanin Synthesis. The role of ZAG in production of melanin is different. In vitro, increased ZAG can decrease melanin production by decreasing levels of tyrosinase protein and its activity, which are the key step for melanin synthesis. Furthermore, ZAG decreases melanin production in vivo, suggesting that ZAG has a different mechanism in vivo and in vitro. Collectively, it appears that the minimal level of ZAG is required for melanin production [7].

It has also been shown that ZAG is produced by normal epidermal keratinocytes, where its expression improves with cellular differentiation [7, 42]. It appears that ZAG as a keratinocyte-derived factor influences melanocyte behavior, including melanocyte proliferation, dendricity, and melanin synthesis [7, 43, 44].

Tumor necrosis factor- α (TNF- α) also inhibits melanin synthesis by human primary melanoma, but it appears that ZAG inhibits melanin production via a TNF-independent mechanism [7].

3.5. Immunoregulation. Due to high degree of structural similarities to MHC-I, ZAG is considered as a member of immunoglobulin superfamily [7]. The members of this family present peptides to cytotoxic T cells [7, 45]. It has a role in the expression of the immune response [7]. In contrast to MHC-I, ZAG does not require peptides and $\beta 2$ -microglobulin for folding [7, 46]. The most plausible role of ZAG in immunity is through its capacity for binding and presenting lipidic ligands to T cells [7]. Although the role of ZAG in immunoregulation cannot be denied, the immune system does not seem to be significantly altered in the absence of ZAG [7, 18].

3.6. Cell Adhesion. ZAG is effective in attaining the properties of cell adhesion between cells and extracellular matrices [7]. This function appears to be due to the presence of Arg-Gly-Asp in $\alpha 3$ domain [7, 47]. Integrins require divalent cations such as Mg^{2+} and Mn^{2+} for mediating cell adhesion, and surprisingly, the presence of Mg^{2+} and Mn^{2+} is also needed for cell adhesion by ZAG. This finding describes the role of ZAG in the integrin-mediated adhesion. Other mechanisms for ZAG-mediated cell adhesion have been described [7].

3.7. RNase Activity. It has been shown that the RNase activity of ZAG has similarities to other RNases such as human pancreatic RNase [7, 48]. The RNase activity may be important for the physiologic function of ZAG. In various organs, the biological activity of ZAG is associated with infection, immunoregulation, and antitumor activity. It appears that ZAG as a soluble molecule can degrade and eliminate byproduct of RNA processing reactions within cells, as well as incorrectly synthesized or damaged RNA [7]. Degraded RNA can be used as nutrients in cells for reproduction of RNA pool [7, 49].

3.8. As a Carrier Protein. The crystallographic studies of ZAG have shown that its groove can bind small hydrophobic ligands [7, 12]. It appears that ZAG via binding to lipid-like molecules in its groove can regulate lipid metabolism. The common determinant with nephritogenic urinary glycoprotein and serum is ZAG; hence, it is concluded that the plasma ZAG may function as a carrier protein of the nephritogenic renal glycoprotein [7].

3.9. Tumor Proliferation. The role of ZAG in malignancies is different. In one hand, ZAG indirectly plays a role in hindering tumor progression via downregulating cyclin-dependent kinase, which regulates G2-M transition, a rate limiting step in the cell cycle. Moreover, ZAG is actively involved in inhibition of tumor growth and proliferation via its linking with immune system [7]. The capacity of macroglobulins such as ZAG for binding hydrolases makes them to prevent the enzyme-mediated tumor invasion [7, 21]. Furthermore, an excess of macroglobulin/hydrolase complexes can activate apoptosis. On the other hand, the progressing tumors express many receptors to macroglobulins such as ZAG, which are carriers of some cytokines and growth factors essential for proliferation [7].

3.10. Growth Control. In Jiexian red cattle, polymorphism of four loci at the coding region of the ZAG gene has been shown including in Z1, Z2, Z3, and Z4. In one study, Guo et al. showed that Z4 locus can be one of the markers of growth traits in these animals [13].

4. Pathologic Roles of ZAG in Human

The concentration of ZAG in serum has been shown to increase significantly in carcinomas [7]. Hence, it is considered as a good marker for detecting prostate [5, 7, 50], breast,

oral, and epidermal carcinomas [7]. The ZAG expression in prostate cancer epithelial cells is inversely associated with Gleason's grade on pathology [6, 50]. This inverse association between Gleason's grade and rising serum ZAG level is similar to that seen with prostate-specific antigen [50]. It is identified that ZAG is increased in the urine samples of patients with bladder cancer [7, 51]. Irmak et al. showed that ZAG is prominent in tumor cells at the bladder tumor invasion front [51]. It appears that ZAG is a clinically important protein, which is directly involved in different types of tumor proliferation [7]; however the exact mechanism by which ZAG results in this proliferation has not been known. This finding is different from other studies which have shown a hindering role for ZAG in tumor proliferation.

Some studies have demonstrated that low levels of ZAG expression correlate with metastatic potential and a higher risk of recurrence in prostate cancer, suggesting that ZAG can act as an inhibitor of proliferation [6, 16, 52]. Furthermore, some pathological states associated with an increase in epithelial cell proliferation, such as psoriasis and polycystic kidney disease, are accompanied with decreased ZAG expression [16]. It appears that results are different and inverse in the role of ZAG in cell proliferation.

Moreover, there is a higher level of ZAG in the well-differentiated tumors than that in the moderately or poorly differentiated tumors [5, 7]. It was expressed predominantly in tumors of apocrine and eccrine differentiations [7]; so, ZAG can be considered as a marker of maturation and differentiation.

Cancer cachexia is characterized by progressive loss of adipose tissue due to increased lipolysis, resulting in the depletion of 85% of the adipose tissue mass and 30% of weight. A potential mediator of this increased lipolysis is a lipid-mobilising factor (LMF) which has been shown to be identical with the plasma ZAG [20]. In cachectic cancer patients, ZAG mRNA is upregulated while leptin mRNA is decreased [1].

The role of ZAG in cancer cachexia was described by Bing et al. [22]. ZAG can be purified from the urine of patients with cancer cachexia [17]. In cancer cachexia, morphological examination shows marked remodeling of adipose tissue. This remodeling is characterized by shrunken adipocytes with a major reduction in cell size and increased fibrosis in the tissue matrix [53]. It appears that increased lipolysis is a key factor underlying fat loss in cachexia, while inhibition of adipocyte development and lipid deposition may also contribute [54]. In cachexia, both LMF and ZAG can induce lipolysis directly by a cyclic AMP-mediated process, and this is initiated through binding to a β 3-adrenoreceptor [20]. Fasting levels of serum cortisol have been revealed to be significantly higher in weight-losing patients with stage IV breast cancer than those who have no weight loss [20, 33]. This suggests that the changes in ZAG expression in adipose tissue in cancer cases can be secondary to increase in serum cortisol level [20]. Furthermore, as another mechanism for lipolysis in cachexia, Sanders and Tisdale demonstrated that ZAG can induce uncoupling protein-1 (UCP-1) expression in brown, but not white, adipose tissue, which can be attenuated by β 3-adrenoreceptor antagonist. Their study showed

that ZAG can directly influence UCP expression, which is responsible for lipid utilization during cancer cachexia [26].

The ZAG is involved in the pathogenesis of proliferative diabetic retinopathy [7, 54]. It is also a biomarker for glomerular disease. It has been revealed that ZAG is among the proteins excreted in urine of microalbuminuria-positive diabetes patients [7]. In cases of chronic hemodialysis, median ZAG serum level is elevated [19]. Jia et al. showed that ZAG can be of potential biomarkers for early noninvasive diagnosis of the acute rejection after renal transplantation [55]. Schmitt et al. showed that aged mouse kidneys displayed a reduced epithelial proliferative reserve due to increased proximal tubular expression of ZAG. Their findings revealed ZAG implication in epithelial proliferative inhibition, which is different from other previous studies that have shown the proliferative role for ZAG. It appears that ZAG can influence the turnover of extracellular matrix components; hence, not only ZAG is a novel regulator of cell proliferation in the aging kidneys and as a modifier of the aging phenotype but also it may be implicated in the regulation of renal interstitial homeostasis [16].

The ZAG is a marker for response to thalidomide-based therapy in patients with multiple myeloma. Rajpal et al. showed that ZAG along with vitamin D-binding protein, serum amyloid-A protein, and β 2-microglobulin has significantly higher concentration in nonresponders to thalidomide-based induction therapy compared to responders, while haptoglobin has a lower concentration [56].

The ZAG is one of the biomarkers in multiple sclerosis. Tumani et al. have shown that the level of ZAG in cerebrospinal fluid is downregulated in the episode of multiple sclerosis [57].

Findings have showed that ZAG can be as a biomarker for human metabolic alterations [58]. The ZAG is decreased in liver fibrosis in hepatitis C and cirrhosis, which suggests the role of ZAG in their pathogenesis [7]. Regarding these findings, it appears that upregulation of ZAG can be a promising therapeutic target for metabolic syndrome [30].

5. An Overview of Vitiligo

Vitiligo is the most common depigmenting skin disorder [59], characterized by acquired, progressive, and circumscribed amelanosis of the skin and hair [60]. It commonly begins in childhood or young adulthood. Its incidence in males and females is equal [61, 62].

The pathogenesis of this disorder is uncertain, but it appears to be dependent on the interaction of genetic, immunological, and neurological factors [8]. The melanocytes in vitiligo are degenerated and seem to be replaced by Langerhans cells [8, 63]. The linkage signals on chromosomes 1, 7, and 17 in Caucasian families with generalized vitiligo and associated autoimmune diseases have been reported [64, 65]. Some of the suggested pathogeneses include impaired melanocyte migration and/or proliferation, accumulation of toxic compounds [8, 66], infections, and psychological, neural, autoimmune, and autocytotoxic factors [8].

Many patients with generalized vitiligo have serum autoantibodies and circulating autoreactive T cells against melanocytes and melanocyte components [67]. Moreover, increased levels of soluble interleukin (IL)-2 receptor, IL-6, and IL-8 have been found, which further suggest the role of T-cell activation in the vitiligo pathogenesis [68]. Furthermore, detection of significantly higher expression of IL-6 and tumor necrosis factor (TNF)- α in vitiligo skin, compared with normal skin, reveals an imbalance of epidermal cytokines at sites of lesions [8, 69].

It appears that there may be a relationship between stress and the development of vitiligo, because vitiligo patients tend to have higher scores for anxiety, depression, adjustment disorders, obsessive symptoms, and hypochondria [8, 70].

A new theory is emphasizing that depigmentation in vitiligo patches results from a chronic detachment of melanocytes that is proposed to be designated as melanocytorrhagy, which is possibly related to increased susceptibility to mechanical and other types of stresses [8, 71, 72].

It has been demonstrated that repigmentation occurs in 10–20% of patients [8, 73, 74]. Sun protection of the vitiliginous areas with sunblocks is important [8, 75, 76] for preventing photodamage and lessening the chance of the Koebner phenomenon [8]. Camouflage products and self-tanning dyes can help to improve lesions cosmetically [8, 77].

Studies have shown that topical steroids and narrowband UVB monotherapy are the most effective and safest forms of treatment for localized and generalized vitiligo, respectively [8, 77]. Some of other important treatments of vitiligo include photochemotherapy, intralesional and oral steroids, calcipotriol, topical fluorouracil, topical minoxidil, oral L-phenylalanine, surgical producers, 308 nm excimer laser, and homeopathy [8]. In one clinical trial, we have demonstrated that zinc also is effective in the treatment of vitiligo [61].

6. Probable Association between ZAG and Vitiligo

For the first time, we pointed the probable association which might be present between ZAG and vitiligo [8, 64]. It appears that most of the suggested pathogeneses of vitiligo can be attributed to decrease in ZAG as follows:

- (i) Studies have revealed that ZAG as a keratinocyte-derived factor influences melanocyte proliferation and dendricity [7, 43, 44]. Moreover, ZAG can be considered as a marker of maturation and differentiation of cells [7]. Hence, in vitiligo, the lack of ZAG is expected to inhibit melanocyte proliferation, and if we consider the Langerhans cells (placed instead of melanocytes in vitiligo sites) as poorly differentiated melanocytes, this impairing in the process of maturation or differentiation of melanocytes can be attributed to the lack of ZAG.
- (ii) Some patients with vitiligo have serum autoantibodies and circulating autoreactive T cells against

melanocytes and melanocyte components [68]. Studies have shown that ZAG is effective in immunoregulation [7, 18, 45, 46]. Therefore, ZAG can be effective in prevention of vitiligo by immunoregulation.

- (iii) It has been revealed that ZAG is effective in attaining the properties of cell adhesion between cells and extracellular matrices [7]. We know that a chronic detachment of melanocytes has been suggested as a recently identified pathogenesis for vitiligo [8, 71, 72]. Hence, it is expected the melanocyte adhesions to the other cells in epidermis to be impaired in the lack of ZAG.
- (iv) In whitish patches of vitiligo, the expression of TNF- α is high [8, 69]. Some studies revealed that TNF- α can decrease ZAG expression and secretion [4, 25]; hence, increased expression of this cytokine in the site of vitiligo can result in a decrease of ZAG expression.
- (v) Topical steroids are the most effective and safest forms of treatment for vitiligo, especially for the localized one [8, 77]. Studies have shown that steroids are able to increase ZAG expression [20, 22, 23]. Regarding these findings we can conclude that steroids are effective in treating vitiligo via enhancing ZAG.
- (vi) As a hypothesis, Bagherani et al. suggested that zinc might be effective in the treatment of vitiligo [64]. Some studies have shown that zinc can precipitate ZAG [8–10]. We can conclude that zinc, by precipitating circulating ZAG in the site of vitiligo, can be effective in treatment of this disease.
- (vii) The linkage signals on chromosome 7 in patients with generalized vitiligo and associated autoimmune diseases have been reported [64, 67]. Surprisingly, ZAG gene is located on the chromosome 7 [7]. This association between these findings appears to not be accidental.
- (viii) Some findings have shown that the minimal level of ZAG is required for melanin production [7]. Hence, it is expected that lack of ZAG can result in whitish patches of vitiligo. Although this hypothesis is not strongly justifying vitiligo pathogenesis because, in the process of vitiligo, the melanocytes are impaired but not melanogenesis, we can consider this theory for vitiligo-like diseases such as postinflammatory hypopigmentation.

7. Conclusion

Regarding mentioned subjects, the association between vitiligo and ZAG must be confirmed in one robust study *in vitro* and *in vivo*. If we can confirm this association, this discovery will result in a big progression in the field of treatment of this debilitating disease.

References

- [1] T. Mracek, N. A. Stephens, D. Gao et al., "Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients," *British Journal of Cancer*, vol. 104, no. 3, pp. 441–447, 2011.
- [2] T. Mracek, Q. Ding, T. Tzanavari et al., "The adipokine zinc- α 2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity," *Clinical Endocrinology*, vol. 72, no. 3, pp. 334–341, 2010.
- [3] T. Tzanavari, C. Bing, and P. Trayhurn, "Postnatal expression of zinc- α 2-glycoprotein in rat white and brown adipose tissue," *Molecular and Cellular Endocrinology*, vol. 279, no. 1–2, pp. 26–33, 2007.
- [4] Y. Bao, C. Bing, L. Hunter, J. R. Jenkins, M. Wabitsch, and P. Trayhurn, "Zinc- α 2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes," *FEBS Letters*, vol. 579, no. 1, pp. 41–47, 2005.
- [5] L. P. Hale, D. T. Price, L. M. Sanchez, W. Demark-Wahnefried, and J. F. Madden, "Zinc α -2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer," *Clinical Cancer Research*, vol. 7, no. 4, pp. 846–853, 2001.
- [6] A. Descazeaud, A. de la Taille, Y. Allory et al., "Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system," *Prostate*, vol. 66, no. 10, pp. 1037–1043, 2006.
- [7] M. I. Hassan, A. Waheed, S. Yadav, T. P. Singh, and F. Ahmad, "Zinc α 2-glycoprotein: a multidisciplinary protein," *Molecular Cancer Research*, vol. 6, no. 6, pp. 892–906, 2008.
- [8] R. Yaghoobi, M. Omidian, and N. Bagherani, "Vitiligo: a review of the published work," *Journal of Dermatology*, vol. 38, no. 5, pp. 419–431, 2011.
- [9] L. P. Hale, "Zinc α -2-glycoprotein regulates melanin production by normal and malignant melanocytes," *Journal of Investigative Dermatology*, vol. 119, no. 2, pp. 464–470, 2002.
- [10] W. Burgi and K. Schmid, "Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma," *The Journal of Biological Chemistry*, vol. 236, pp. 1061–1074, 1961.
- [11] T. Araki, F. Gejyo, K. Takagaki et al., "Complete amino acid sequence of human plasma Zn- α 2-glycoprotein and its homology to histocompatibility antigens," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 85, no. 3, pp. 679–683, 1988.
- [12] L. C. McDermott, J. A. Freel, A. P. West, P. J. Bjorkman, and M. W. Kennedy, "Zn- α 2-glycoprotein, an MHC class I-related glycoprotein regulator of adipose tissues: modification or abrogation of ligand binding by site-directed mutagenesis," *Biochemistry*, vol. 45, no. 7, pp. 2035–2041, 2006.
- [13] Y. K. Guo, H. Chen, B. Zhang et al., "Polymorphisms of ZAG gene with growth traits in Jiaxian red cattle," *Yi Chuan*, vol. 30, no. 11, pp. 1417–1420, 2008.
- [14] C. Huang, N. Na, L. Huang, D. He, and J. Ouyang, "TEMED enhanced photoluminescent imaging detection of proteins in human serum using quantum dots after PAGE," *Journal of Proteome Research*, vol. 9, no. 11, pp. 5574–5581, 2010.
- [15] L. M. Sánchez, A. J. Chirino, and P. Bjorkman, "Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules," *Science*, vol. 283, no. 5409, pp. 1914–1919, 1999.
- [16] R. Schmitt, A. Marlier, and L. G. Cantley, "Zag expression during aging suppresses proliferation after kidney injury," *Journal of the American Society of Nephrology*, vol. 19, no. 12, pp. 2375–2383, 2008.
- [17] T. Mracek, D. Gao, T. Tzanavari et al., "Downregulation of zinc- α 2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor- α in adipocytes," *Journal of Endocrinology*, vol. 204, no. 2, pp. 165–172, 2010.
- [18] V. Rolli, M. Radosavljevic, V. Astier et al., "Lipolysis is altered in MHC class I zinc- α 2-glycoprotein deficient mice," *FEBS Letters*, vol. 581, no. 3, pp. 394–400, 2007.
- [19] A. Philipp, S. Kralisch, A. Bachmann et al., "Serum levels of the adipokine zinc- α 2-glycoprotein are increased in chronic hemodialysis," *Metabolism*, vol. 60, no. 5, pp. 669–672, 2011.
- [20] S. T. Russell and M. J. Tisdale, "The role of glucocorticoids in the induction of zinc- α 2-glycoprotein expression in adipose tissue in cancer cachexia," *British Journal of Cancer*, vol. 92, no. 5, pp. 876–881, 2005.
- [21] S. T. Russell, T. P. Zimmerman, B. A. Domin, and M. J. Tisdale, "Induction of lipolysis in vitro and loss of body fat in vivo by zinc- α 2-glycoprotein," *Biochimica et Biophysica Acta*, vol. 1636, no. 1, pp. 59–68, 2004.
- [22] C. Bing, Y. Bao, J. Jenkins et al., "Zinc- α 2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 8, pp. 2500–2505, 2004.
- [23] S. T. Russell and M. J. Tisdale, "Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia," *Prostaglandins Leukotrienes and Essential Fatty Acids*, vol. 72, no. 6, pp. 409–414, 2005.
- [24] M. M. Brysk, G. Lei, P. Selvanayagam, H. Brysk, S. K. Tyring, and I. Arany, "Modulation by interferon- γ of zinc- α 2-glycoprotein gene expression in human epithelial cell lines," *Anticancer Research*, vol. 17, no. 5A, pp. 3387–3392, 1997.
- [25] D. Gao, P. Trayhurn, and C. Bing, "Macrophage-secreted factors inhibit ZAG expression and secretion by human adipocytes," *Molecular and Cellular Endocrinology*, vol. 325, no. 1–2, pp. 135–142, 2010.
- [26] P. M. Sanders and M. J. Tisdale, "Effect of zinc- α 2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue," *Cancer Letters*, vol. 212, no. 1, pp. 71–81, 2004.
- [27] C. Bing, T. Mracek, D. Gao, and P. Trayhurn, "Zinc- α 2-glycoprotein: an adipokine modulator of body fat mass," *International Journal of Obesity*, vol. 34, no. 11, pp. 1559–1565, 2010.
- [28] F. Y. Gong, S. J. Zhang, J. Y. Deng et al., "Zinc- α 2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue," *International Journal of Obesity*, vol. 33, no. 9, pp. 1023–1030, 2009.
- [29] F. Y. Gong, J. Y. Deng, H. J. Zhu, H. Pan, L. J. Wang, and H. B. Yang, "Fatty acid synthase and hormone-sensitive lipase expression in liver are involved in zinc- α 2-glycoprotein-induced body fat loss in obese mice," *Chinese Medical Sciences Journal*, vol. 25, no. 3, pp. 169–175, 2010.
- [30] M. P. Marrades, J. A. Martínez, and M. J. Moreno-Aliaga, "ZAG, a lipid mobilizing adipokine, is downregulated in human obesity," *Journal of Physiology and Biochemistry*, vol. 64, no. 1, pp. 61–66, 2008.
- [31] S. T. Russell and M. J. Tisdale, "Studies on the antiobesity effect of zinc- α 2-glycoprotein in the ob/ob mouse," *International Journal of Obesity*, vol. 35, no. 3, pp. 345–354, 2011.
- [32] P. T. Todorov, T. M. McDevitt, D. J. Meyer, H. Ueyama, I. Ohkubo, and M. J. Tisdale, "Purification and characterization of a tumor lipid-mobilizing factor," *Cancer Research*, vol. 58, no. 11, pp. 2353–2358, 1998.

- [33] M. L. Knapp, S. Al-Sheibani, P. G. Riches, I. W. F. Hanham, and R. H. Phillips, "Hormonal factors associated with weight loss in patients with advanced breast cancer," *Annals of Clinical Biochemistry*, vol. 28, no. 5, pp. 480–486, 1991.
- [34] K. Eckardt, A. Schober, B. Platzbecker et al., "The adipokine zinc- α 2-glycoprotein activates AMP kinase in human primary skeletal muscle cells," *Archives of Physiology and Biochemistry*, vol. 117, no. 2, pp. 88–93, 2011.
- [35] S. T. Russell and M. J. Tisdale, "Studies on the anti-obesity activity of zinc- α 2-glycoprotein in the rat," *International Journal of Obesity*, vol. 35, no. 5, pp. 658–665, 2011.
- [36] S. T. Russell and M. J. Tisdale, "Mechanism of attenuation of skeletal muscle atrophy by zinc- α 2-glycoprotein," *Endocrinology*, vol. 151, no. 10, pp. 4696–4704, 2010.
- [37] L. E. Olofsson, B. Olsson, T. Lystig et al., "Preliminary report: Zn-alpha2-glycoprotein genotype and serum levels are associated with serum lipids," *Metabolism*, vol. 59, no. 9, pp. 1316–1318, 2010.
- [38] D. Stejskal, M. Karpíšek, H. Reutová, P. Stejskal, H. Kotolová, and P. Kollár, "Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA," *Clinical Biochemistry*, vol. 41, no. 4-5, pp. 313–316, 2008.
- [39] C. Reichel, "Identification of zinc-alpha-2-glycoprotein binding to clone AE7A5 antihuman EPO antibody by means of nano-HPLC and high-resolution high-mass accuracy ESI-MS/MS," *Journal of Mass Spectrometry*, vol. 43, no. 7, pp. 916–923, 2008.
- [40] G. Frenette, M. Thabet, and R. Sullivan, "Polyol pathway in human epididymis and semen," *Journal of Andrology*, vol. 27, no. 2, pp. 233–239, 2006.
- [41] Z. Ding, F. Qu, W. Guo, X. Ying, M. Wu, and Y. Zhang, "Identification of sperm forward motility-related proteins in human seminal plasma," *Molecular Reproduction and Development*, vol. 74, no. 9, pp. 1124–1131, 2007.
- [42] G. Lei, I. Arany, P. Selvanayagam, S. Rajaraman, S. Ram, and H. Brysk, "Detection and cloning of epidermal zinc- α 2-glycoprotein cDNA and expression in normal human skin and in tumors," *Journal of Cellular Biochemistry*, vol. 67, pp. 216–222, 1997.
- [43] P. R. Gordon and B. A. Gilchrest, "Human melanogenesis is stimulated by diacylglycerol," *Journal of Investigative Dermatology*, vol. 93, no. 5, pp. 700–702, 1989.
- [44] P. R. Gordon, C. P. Mansur, and B. A. Gilchrest, "Regulation of human melanocyte growth, dendricity and melanization by keratinocyte derived factors," *Journal of Investigative Dermatology*, vol. 92, no. 4, pp. 565–572, 1989.
- [45] M. Matsumura, D. H. Fremont, P. A. Peterson, and I. A. Wilson, "Emerging principles for the recognition of peptide antigens by MHC class I molecules," *Science*, vol. 257, no. 5072, pp. 927–934, 1992.
- [46] D. M. Hill, T. Kasliwal, E. Schwarz et al., "A dominant negative mutant β 2-microglobulin blocks the extracellular folding of a major histocompatibility complex class I heavy chain," *Journal of Biological Chemistry*, vol. 278, no. 8, pp. 5630–5638, 2003.
- [47] G. Lie, H. Brysk, I. Arany et al., "Characterization of Zinc- α (2)-glycoprotein as a cell adhesion molecule that inhibits the proliferation of an oral tumor cell line," *Journal of Cellular Biochemistry*, vol. 75, pp. 160–169, 1999.
- [48] G. Lei, I. Arany, S. K. Tying, H. Brysk, and M. M. Brysk, "Zinc- α 2-glycoprotein has ribonuclease activity," *Archives of Biochemistry and Biophysics*, vol. 355, no. 2, pp. 160–164, 1998.
- [49] E. V. Koonin and M. P. Deutscher, "RNase T shares conserved sequence motifs with DNA proofreading exonucleases," *Nucleic Acids Research*, vol. 21, no. 10, pp. 2521–2522, 1993.
- [50] G. O'Hurley, A. O'Grady, P. Smyth et al., "Evaluation of Zinc- α 2-glycoprotein and proteasome subunit β -type 6 expression in prostate cancer using tissue microarray technology," *Applied Immunohistochemistry and Molecular Morphology*, vol. 18, no. 6, pp. 512–517, 2010.
- [51] S. Irmak, D. Tilki, J. Heukeshoven et al., "Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer," *Proteomics*, vol. 5, no. 16, pp. 4296–4304, 2005.
- [52] J. Lapointe, C. Li, J. P. Higgins et al., "Gene expression profiling identifies clinically relevant subtypes of prostate cancer," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 3, pp. 811–816, 2004.
- [53] C. Bing and P. Trayhurn, "New insights into adipose tissue atrophy in cancer cachexia," *Proceedings of the Nutrition Society*, vol. 68, no. 4, pp. 385–392, 2009.
- [54] M. García-Ramírez, F. Canals, C. Hernández et al., "Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy," *Diabetologia*, vol. 50, no. 6, pp. 1294–1303, 2007.
- [55] X. Jia, C. Gan, K. Xiao et al., "Detection of urinary biomarkers for early diagnosis of acute renal allograft rejection by proteomic analysis," *Proteomics*, vol. 3, no. 6, pp. 694–704, 2009.
- [56] R. Rajpal, P. Dowling, J. Meiller et al., "A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients," *Proteomics*, vol. 11, no. 8, pp. 1391–1402, 2011.
- [57] H. Tumaní, V. Lehmensiek, D. Rau et al., "CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis," *Neuroscience Letters*, vol. 452, no. 2, pp. 214–217, 2009.
- [58] Y. Yilmaz, O. Yonal, F. Eren et al., "Serum zinc- α 2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease," *Clinical Chemistry and Laboratory Medicine*, vol. 49, no. 1, pp. 93–97, 2011.
- [59] M. I. Helmy, E. I. M. A. Gayyar, S. Hawas, and E. A. Eissa, "Role of oxidative stress in the pathogenesis of vitiligo," *Journal of Pan Arab League of Dermatologists*, vol. 15, pp. 97–105, 2004.
- [60] P. Shameer, P. V. S. Prasad, and P. K. Kaviarasan, "Serum zinc level in vitiligo: a case control study," *Indian Journal of Dermatology, Venereology and Leprology*, vol. 71, no. 3, pp. 206–207, 2005.
- [61] R. Yaghoobi, M. Omidian, and N. Bagherani, "Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial," *BMC Dermatology*, vol. 11, article 7, 2011.
- [62] K. Wolff, L. A. Goldsmith, B. A. Gilchrest, A. S. Paller, and D. J. Leffell, *Fitzpatrick's Dermatology in General Medicine*, Mac Graw Hill, 7 edition, 2007.
- [63] M. S. Birbeck, A. S. Breathnach, and J. D. Overall, "An electron microscope study of basal melanocytes and high level-clear cells (Langerhans cells) in vitiligo," *Journal of Investigative Dermatology*, vol. 37, pp. 51–54, 1961.
- [64] N. Bagherani, R. Yaghoobi, and M. Omidian, "Hypothesis: zinc can be effective in treatment of vitiligo. Indian," *The Journal of Dermatology*, vol. 56, pp. 497–501, 2011.

- [65] Y. Jin, S. L. Riccardi, K. Gowan, P. R. Fain, and R. A. Spritz, "Fine-mapping of vitiligo susceptibility loci on chromosomes 7 and 9 and interactions with NLRP1 (NALP1)," *Journal of Investigative Dermatology*, vol. 130, no. 3, pp. 774–783, 2010.
- [66] I. C. Le Poole, P. K. Das, R. M. J. G. J. van den Wijngaard, J. D. Bos, and W. Westerhof, "Review of the etiopathomechanism of vitiligo: a convergence theory," *Experimental Dermatology*, vol. 2, no. 4, pp. 145–153, 1993.
- [67] R. E. Boissy and R. A. Spritz, "Frontiers and controversies in the pathobiology of vitiligo: separating the wheat from the chaff," *Experimental Dermatology*, vol. 18, no. 7, pp. 583–585, 2009.
- [68] R. L. Mandelcorn-Monson, N. H. Shear, E. Yau et al., "Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients," *Journal of Investigative Dermatology*, vol. 121, no. 3, pp. 550–556, 2003.
- [69] S. Moretti, A. Spallanzani, L. Amato et al., "New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions," *Pigment Cell Research*, vol. 15, no. 2, pp. 87–92, 2002.
- [70] L. Manolache and V. Benea, "Stress in patients with alopecia areata and vitiligo," *Journal of the European Academy of Dermatology and Venereology*, vol. 21, no. 7, pp. 921–928, 2007.
- [71] Y. Gauthier, M. Cario-Andre, S. Lepreux, C. Pain, and A. Taïeb, "Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo," *British Journal of Dermatology*, vol. 148, no. 1, pp. 95–101, 2003.
- [72] Y. Gauthier, M. Cario-Andre, and A. Taïeb, "A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?" *Pigment Cell Research*, vol. 16, no. 4, pp. 322–332, 2003.
- [73] L. Torello, G. Alessia, F. Zanieri, R. Colucci, and S. Moretti, "Vitiligo: new and emerging treatments," *Dermatologic Therapy*, vol. 21, no. 2, pp. 110–117, 2008.
- [74] J. Castanet and J. P. Ortonne, "Pathophysiology of vitiligo," *Clinics in Dermatology*, vol. 15, no. 6, pp. 845–851, 1997.
- [75] M. G. Lebwohl, W. R. Heymann, J. Berth-Jones, and I. Coulson, *Treatment of Skin Disease: Comprehensive Therapeutic Strategies*, Mosby Elsevier, 2nd edition, 2006.
- [76] T. Burns, S. Breathnach, N. Cox, and C. Griffiths, *Rook's Textbook of Dermatology*, vol. 2, Oxford Blackwell Science, 7th edition, 2004.
- [77] M. E. Whitton, D. M. Ashcroft, and U. González, "Therapeutic interventions for vitiligo," *Journal of the American Academy of Dermatology*, vol. 59, no. 4, pp. 713–717, 2008.